Influence of Time in Treatment and Follow-Up Duration on Methadone Treatment Outcomes
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Data for 422 methadone treatment clients in the National Treatment Improvement Evaluation Study (NTIES) were analyzed. Clients maintained continuously in methadone treatment for longer than 12 months and clients who leftbetween 3–12 months were compared with clients treated for less than 3 months. Additionally, clients treated for 3–12 months who had short follow-up periods (6-month average) were compared with 3–12-month clients with long follow-up periods (11-month average). Positive treatment outcomes includinglower drug use, reduced risk of viral infectionand sexually transmitted disease (through needle sharing and multiple sex partners), and less criminality wereassociated with both longer duration treatment and shorter follow-up periods. The findings suggested that continuous methadone treatment of 12 or more months is optimal, whereas stays of less than3 months may be ineffective. Furthermore, stays of 3–12 months are likelyto be beneficial over a relatively short time span, for example 6 months.
- Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome. New York: Springer-Verlag.
- Fulco, C. E., Liverman, C. T., & Earley, L. E. (Eds.). (1995). Development of medications for the treatment of opiate and cocaine dependence: Issues for the government and private sector. Washington, DC: National Academy Press.
- Gerstein, D. R., Johnson, R. A., Harwood, H. J., Fountain, D. L., Suter, N., & Malloy, K. M. (1994). Evaluating recovery services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento,CA: State of California, Department of Alcohol and Drug Programs.
- Greenfield, L. (1999). Methadone treatment outcomes in the National Treatment Improvement Evaluation Study. Submitted to the Center for Substance Abuse Treatment under the National Evaluation Data Services contract. Fairfax, VA: Caliber Associates.
- Hubbard, R. L., Craddock, S.G., Flynn, P. M., Anderson, J., & Etheridge, R.M. (1997). Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors, 11, 261–278.
- Hubbard, R. L., Marsden, M. E., Rachal, J. V., Harwood, H. J., Cavanaugh, E. R., & Ginzburg, H. M. (1989). Drug abuse treatment: National study of effectiveness (pp. 71–98). Chapel Hill: University of North Carolina Press.
- Joseph, H., & Appel, P. (1993). Historical perspectives and public health issues. In M.W. Parrino (Ed.), State methadone treatment guidelines (Treatment Improvement Protocol No. 1, pp. 11–24). Rockville, MD: Center for Substance Abuse Treatment.
- Koenig, L., Denmead, G., Nguyen, Harrison, M., & Harwood, R. (1999). The costs and benefits of substance abuse treatment: Findings from the National Treatment Improvement Evaluation Study (NTIES). Submitted to the Center for Substance Abuse Treatment. Fairfax, VA: Caliber Associates.
- Lowinson, J. H., Payte, J. T., Salsitz, E., Joseph, H., Marion, I. J., & Dole, V. P. (1997). Methadone maintenance. In J.H. Lowinson, P. Ruiz, R. B. Millman, & J.G. Landgrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed., pp. 405–414). Baltimore, MD: Williams and Wilkins.
- Magura, S., Nwakeze, P. C., & Demsky, S. (1998). Pre-and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction, 93, 51–60.
- Metzger, D. S., Woody, G. E., McLellan, A.T., O'Brien, C. P., Druly, P., Navaline, H., DePhilippis, D., Stolley, P., & Abrutyn, E. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective followup. Journal of Acquired Immune Deficiency Syndromes, 6, 1049–1056.
- National Opinion Research Center (NORC). (1997). Final report: National Treatment Improvement Study. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment.
- Novick, D. M., Joseph, H., Croxson, T. S., Salsitz, E. A., Wang, G., Richman, B. L., Poretsky, L., Keefe, J.B., & Whimbey, E. (1990). Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine, 150, 97–99.
- Office of Applied Studies. (1998). National Household Survey on Drug Abuse: Main Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- Office of Applied Studies. (1999). Drug Abuse Warning Network, 1999. Rockville, MD: Substance Abuse and Mental Health Services Administration.
- Rettig, R. A., & Yarmolinsky, A. (Eds.). (1995). Federal regulation of methadone treatment. Washington, DC: National Academy Press.
- Simpson, D. D., & Sells, S. B. (1982). Effectiveness of treatment for drug abuse: An overview of the DARP research program. Advances in Alcohol and Substance Abuse, 2, 7–29.
- Simpson, D.D., & Sells, S.B. (1990). Opioid addiction and treatment: 12-year follow-up. Malablar, FL: Reiger.
- Influence of Time in Treatment and Follow-Up Duration on Methadone Treatment Outcomes
Journal of Psychopathology and Behavioral Assessment
Volume 22, Issue 4 , pp 353-364
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links